EN: atrial fibrillation, progression, verapamil, metoprolol NL: atriumfibrilleren, progressie, verapamil, metoprolol
Conditions
Interventions
Patients are randomized to verapamil slow release 240mg once daily or metoprolol slow release 100mg once daily. Dose adjustments (half or double) can be made upon the response to heart rate or blood p
Sponsors
Martini ziekenhuis Groningen
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this trial, a subject must meet all of the following criteria: Patients (age > 18) with symptomatic paroxysmal AF with an indication for rate control medication who participate in the RACE 5 registry. Patients must be able and willing to sign informed consent for the randomised study.
Exclusion criteria
Exclusion criteria: Exclusion criteria are (history of) persistent AF, previous adverse effects to the study drugs, contra-indication for the study drugs (i.e. heart failure with reduced ejection fraction, symptomatic hypotension, atrioventricular conduction disturbance, severe asthma/COPD), history of pulmonary vein isolation (PVI), pregnancy and breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome variable is incidence of AF progression from paroxysmal to persistent AF or the need for PVI. | — |
Secondary
| Measure | Time frame |
|---|---|
| Main secondary outcome variables are AF burden, heart rate, exercise tolerance, symptom severity, quality of life, and costs. | — |
Contacts
Public ContactR.G. Tieleman
Outcome results
None listed